ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2016
Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 Stage III-N2 NSCLC after Induction Chemotherapy and Resection.
Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Development and validation of an interpretable machine learning model for postoperative radiotherapy decision-making in ypN0 breast cancer after neoadjuvant chemotherapy: a real-world study.BMC medical informatics and decision making · 2026Article
- Adjuvant radiotherapy in the era of new peri-operative systemic treatments for surgically resected non-small-cell lung cancer: where do we stand?Translational lung cancer research · 2025Review
- Uncertain resection of highest mediastinal lymph node positive among pN2 non-small cell lung cancer patients: survival analysis of postoperative radiotherapy and driver gene mutations.Japanese journal of radiology · 2023Article
- Article
- Preoperative and postoperative radiotherapy (RT) for non-small cell lung cancer: still an open question.Translational lung cancer research · 2021Review
- Optimizing adjuvant therapy inAnnals of translational medicine · 2020Article
- Article
- Observational
- Multimodality Therapy for N2 Non-Small Cell Lung Cancer: An Evolving Paradigm.The Annals of thoracic surgery · 2019Article
- Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell Lung Cancer.The Annals of thoracic surgery · 2018Article
- Proton therapy for post-operative radiation therapy of non-small cell lung cancer.Translational lung cancer research · 2018Review
- Optimized local therapy for locally advanced non-small cell lung cancer.Journal of thoracic disease · 2017Article
- A closer look at the safety and effectiveness of modern PORT in stage III-N2 non-small cell lung cancer.Journal of thoracic disease · 2017Article
- Postoperative radiotherapy and lung cancer in stage III: helpful or harmful.Journal of thoracic disease · 2017Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
13 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe investigated patients with contemporarily staged and treated stage III-N2 NSCLC treated with induction chemotherapy and surgery with or without postoperative radiotherapy (PORT). We focused on survival and toxicity and investigated what additional PORT may offer in patients with ypN2 status or incomplete resection.
methodsWe identified 161 patients with pathologically proven, resectable stage III-N2 NSCLC from our prospective database who were treated between 1998 and 2012. Of these patients, 150 without progressive disease after chemotherapy underwent resection. Patients with ypN2 status or R1/2 resection received three-dimensional PORT (n = 70) to a dose of 50 to 66 Gy in 2-Gy fractions.
resultsThe mean follow-up time was 49 months. The 5-year overall survival (OS) rate was 35.1% in intention-to-treat analysis; relapse-free survival was 31.8%, the cumulative local recurrence (LR) rate was 50.9%, and the distant metastasis rate was 63.4%. The 5-year OS, relapse-free survival, and cumulative LR and distant metastasis rates were 32.0%, 32.9%, 47.0%, and 63.9% in the PORT group versus 38.1%, 30.7%, 54.1%, and 63.2% in the non-PORT group. These results were not significantly different, even though patients in the PORT group had worse prognostic features. Cardiac toxicity was higher in the non-PORT group (p = 0.02), but pulmonary toxicity was similar (p = 0.15). There was no difference between the two groups regarding dyspnea (p = 0.32), cough (p = 0.37), forced expiratory volume in 1 second (p = 0.30), and diffusing capacity of the lung for carbon monoxide (p = 0.61).
conclusionsA similar outcome (OS, LR, and toxicity) was seen in both patient groups (PORT versus non-PORT group). Despite the limitations of this retrospective study, PORT can be both effective and safe for patients with stage III-N2 NSCLC with an R1/R2 resection or yN2 after induction chemotherapy and surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.